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ABSTRACT

P2X7 is a cell-surface nucleotide receptor that plays a critical role in skeletal
mechanotransduction; however, the signaling pathways mediating these effects are poorly
understood. Previous studies showed that the nucleotide analog benzoylbenzoyl-ATP
induces anabolic gene expression in osteoblastic cells. Our first objective was to
determine whether this effect was mediated by P2X7. Inhibition of anabolic gene
expression by a P2X7-specific antagonist established involvement of this receptor. Our
second objective was to investigate the role of lipid mediators, lysophosphatidic acid
(LPA) and prostaglandin (PG), both of which are produced in response to P2X7
activation. The effect of P2X7 on expression of the anabolic gene Ptgs2 was abolished by
an LPA receptor antagonist or inhibition of PG synthesis. Furthermore, in the absence of
nucleotide, LPA and PGE2 synergistically stimulated Ptgs2 expression. Thus, LPA and
PG signaling pathways appear to be necessary and sufficient to mediate the effect of
P2X7 on Ptgs2 expression.
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INTRODUCTION

1

Orthodontic Tooth Movement

Orthodontic tooth movement is the result of a complex interaction between an applied
force and a physiologic response within the periodontal supporting tissues. Prolonged
forces placed on teeth are responsible for remodeling the adjacent bone. The cellular
processes by which orthodontic induced bone remodeling occurs have been well
described; however, the initial events of mechanotransduction, the process by which
mechanical stimuli are transformed into biological responses, are unclear. Ultimately,
understanding mechanisms by which mechanotransduction arises may permit more
efficient orthodontic tooth movement.
A theoretical model of tooth movement is comprised of three stages: (1) initial
compression of tissues, resulting in an alteration in blood flow associated with pressure
and tension within the periodontal ligament; (2) the initiation and release of chemical
messengers, such as cytokines and prostaglandins (PGs), and (3) further activation of
cells mediating osteogenesis and bone resorption (Proffit, 2012). Within four hours of
sustained force application, levels of cyclic adenosine monophosphate (cAMP) increase
significantly (Proffit, 2012).

cAMP is a second messenger that regulates the

differentiation of osteoclasts (bone removing cells) and osteoblasts (bone forming cells)
(Roberts, 1989). In addition, levels of prostaglandins (PGs), interleukin-1 beta (IL-1)
and nitric oxide (NO) rise in the periodontal ligament (PDL) (Krishnan and Davidovitch,
2006).
The “Pressure-Tension Theory” of orthodontic tooth movement was developed following
classic histologic research in orthodontics (Krishnan and Davidovitch, 2006; Schwarz,
1932). The application of a force to a tooth creates both an area of compression and
tension within the PDL. This leads to an alteration in blood flow and development of
chemical signals triggering downstream cellular responses. On the compression side,
osteoclastic activity prevails and bone resorption ensues. Immediate precursors of
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osteoclasts are present in the PDL and are activated to mature once appropriate signals
have directed them. Additionally, new osteoclasts can be recruited to the PDL from
hematopoietic organs via the blood stream and alveolar bone marrow cavities (Proffit,
2012). On the tension side, osteoblasts are activated directly and bone deposition results.
The coordinated coupling of osteoblasts and osteoclasts is essential to orthodontic tooth
movement (Krishnan and Davidovitch, 2009). Light orthodontic forces are preferable,
since they promote frontal resorption and efficient tooth movement through bone,
whereas heavy forces lead to necrosis of the PDL and undermining resorption (Proffit,
2012).

Undermining resorption results in delayed tooth movement, since the necrotic

area must be completely removed by osteoclasts before tooth movement can occur.
2

Bone cells

Three main types of bone cells regulate bone metabolism: osteoblasts (bone forming
cells), osteoclasts (bone resorbing cells) and osteocytes (terminally differentiated
osteoblasts). These cells respond to various environmental signals, including biological
and mechanical stimuli, to elicit specific responses based on the physiologic needs of
bone. Receptors on the surface of bone cells bind exogenous signals and transmit this
information to the nucleus where gene expression is initiated (Feldman, 2013).
2.1

Osteoblasts

Osteoblasts are derived from mesenchymal stem cells that can also differentiate into other
cell types such as chondrocytes and fibroblasts (Minguell et al., 2001). Osteoblasts carry
receptors that respond to chemical mediators, which play a central role in bone
metabolism (Feldman, 2013).

In order to commit to the osteoblast lineage, a complex

series of transcriptional events must be initiated and maintained by a number of factors
including: bone morphogenetic proteins (BMPs), transforming growth factor-beta (TGFβ), Wnt signaling pathways, insulin-like growth factors (IGFs) and parathyroid hormone
(PTH) (Huang et al., 2007). Runt-related transcription factor-2 (RUNX2) is a critical
transcription factor responsible for osteoblast differentiation (Huang et al., 2007). Early
and late stages of osteoblast differentiation are controlled by Osterix (OSX), which acts
downstream of RUNX2.

The combined effects of RUNX2 and OSX lead to the
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development of a preosteoblast, which expresses type I collagen and bone sialoprotein
(BSP). Development of the mature osteoblast is dependent upon stimulation of activating
transcription factor 4 (ATF-4) with Wnt/β-catenin signaling components. The mature
osteoblast expresses type I collagen, alkaline phosphatase and osteocalcin (OCN), which
are necessary for the formation of osteoid and its subsequent mineralization (Harada and
Rodan, 2003; Robling et al., 2006).
Differential gene expression is important in each stage of development for the osteoblast.
Genes required for the initial activation and proliferation (c-Fos, c-Jun, and c-Myc) and
cell cycle progression (histones and cyclins) are expressed in pre-osteoblasts (Feldman,
2013). Other factors critical to this stage of osteoblast development are: fibroblast
growth factor (FGF), transforming growth factor- (TGF-), insulin-like growth factor-1
(IGF-1), BMPs, and collagen type I (COL1) (Feldman, 2013).
Proliferation of osteoblasts is followed by production and organization of the
extracellular matrix (ECM).
predominates.

In this stage, collagen secretion and cross-linking

Genes involved with skeletal ECM mineralization (e.g. ALP) are

expressed.
The third stage is characterized by a reduction in genes produced in the proliferation
stage and an increase in hydroxyapatite (HA) production in the ECM. Non-collagenous
proteins with HA-regulating abilities (osteopontin (OPN), osteocalcin (OCN) and bone
sialoprotein (BSP)) are expressed during this stage of osteoblast development (Feldman,
2013).
An organic matrix (osteoid), composed of type I collagen, non-collagenous proteins and
proteoglycans, is secreted by mature osteoblasts.

Deposition of calcium phosphate

mineral leads to mineralization of the osteoid. As bone formation continues, osteoblasts
become incorporated into the mineralized osteoid and terminally differentiate into
osteocytes. Osteocytes communicate with one another and osteoblasts via gap junctions.
These intercellular connections are thought to be critical for transmitting signals resulting
from the mechanical stimulation of bone (Bonewald, 1999). Osteocytes express a distinct
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group of genes, including sclerostin (Sost), matrix extracellular phosphoglycoprotein
(Mepe), and dentin matrix protein-1 (Dmp1) (Feng et al., 2003).
The final stage in osteoblast development serves as an editing function for modifications
needed in the ECM (Feldman, 2013). Once bone formation is complete, the majority of
osteoblasts undergo apoptosis. The remaining cells join the osteocyte population or
become bone-lining cells (Clarke, 2008).
Jones et al. described the first responses in osteoblasts after application of a mechanical
stress. The first events are an increase in intracellular free calcium concentration and
hyperpolarization of the membrane potential through the activation of potassium
channels. Phospholipase C (PLC) is activated to release inositol triphosphate. PLC is
thought to allow a positive feedback mechanism in order to keep the mechanosensitive
channels open by further activation of protein kinase C (PKC). Phospholipase A2 (PLA2)
is then activated, acting on the phospholipid membrane to release arachidonic acid,
leading to the production of prostaglandins (PGs) within about 10 minutes. This is
followed by the release of products from the lipooxygenase pathway that ultimately lead
to an increase in cAMP. cAMP mediates phosphorylation reactions in the nucleus and
cytoplasm of the osteoblast, regulating downstream gene expression and bone remodeling
(Jones et al., 1991).
More recently, osteoblasts have been shown to release ATP in response to mechanical
stimulation (Romanello et al., 2001; Romanello et al., 2005; Buckley et al., 2003;
Genetos et al., 2005).
2.2

Osteoclasts

Mononucleated precursors of the monocyte/macrophage lineage fuse to form
multinucleated osteoclasts (Novack and Teitelbaum, 2008).

Two key signaling

molecules are essential to the formation, resorptive activity and survival of osteoclasts:
macrophage-colony-stimulating factor (M-CSF) and receptor activator of NF-B ligand
(RANKL) (Nobuaki et al., 1998). Both M-CSF and RANKL are produced in membranebound and soluble forms by marrow stromal cells and osteoblasts (Boyce and Xing,
2008; Boyle et al., 2003). Osteoprotegerin (OPG), is a decoy protein that binds to
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RANKL, and thus inhibits the binding of RANKL to its receptor RANK (Boyce and
Xing, 2008; Boyle et al., 2003). In binding to RANKL, this decoy protein leads to
inhibition of osteoclast function and induces osteoclast apoptosis.

The function of

osteoclasts is further mediated by complex interactions among several signaling pathways
such as those activated by PTH, calcitonin, vitamin D, tumor necrosis factor (TNF),
estrogen and several interleukins (Ericksen et al, 1986; Feldman, 2013).

PTH,

prostaglandin E2 (PGE2), and vitamin D upregulate RANKL on the surface of osteoblasts,
and thereby stimulate osteoclast activation (Kale et al., 2004; Feldman, 2013).
In order for the osteoclast to begin resorption, it must attach to the bone surface and
activate proton pumps along its ruffled border.

In the acidic environment of the

resorption lacunae, dissolution of bone mineral is possible. Osteoclasts secrete proteases
such as cathepsin K to degrade the organic matrix comprised mainly of type I collagen
(Novack and Teitelbaum, 2008).

Interleukins (IL-1β, IL-6) and PGE2 encourage

osteoclast resorption (Brough et al., 2003). Once resorption is complete, the osteoclast
may migrate to a new site on the bone surface to continue resorbing bone or it may
undergo apoptosis (Novack and Teitelbaum, 2008).
2.3

Osteocytes

Osteocytes are the most abundant bone cells; however, their function is poorly
understood. Some osteoblasts become incorporated in the osteoid as it is produced,
becoming osteocytes.

Since osteocytes are connected to one another by long cell

processes, they are thought to be involved in receiving mechanical signals and
transmitting these stimuli to other cells in bone (Feldman, 2013).
Osteocytes synthesize sclerostin, a protein responsible for acting in a paracrine fashion to
suppress bone formation. Sclerostin, a product of the SOST gene, binds to LRP5/LRP6
receptors to inhibit the Wnt signaling pathway and thus reduces bone formation (Robling
and Turner, 2009). Both PTH and mechanical loading inhibit the effects of sclerostin
(Turner and Pavalko, 1998; Harada and Rodan, 2003; Robling and Turner, 2009).

6
3

Regulation of Bone Remodeling and Mechanotransduction

Osteoblasts and osteoclasts are responsible for maintaining a fine balance between bone
formation and resorption in bone remodeling. Several critical local and systemic factors,
including PTH, insulin-like growth factors (IGFs), estrogen and bone morphogenetic
proteins (BMPs), along with mechanical stimuli, coordinate activity of bone cells to
control skeletal homeostasis (Harada and Rodan, 2003). Resorption and formation are
strictly coupled under physiological conditions; an imbalance may contribute to bone loss
in a variety of skeletal disorders such as osteoporosis and inflammatory diseases
including periodontitis and rheumatoid arthritis (Novack and Teitelbaum, 2008). Bone
remodeling is a necessary element in orthodontic tooth movement.
Each remodeling cycle is initiated by osteoclast precursors, which form osteoclasts that
remove old bone over a period of 2-4 weeks. Preosteoblasts are recruited to the site after
a reversal phase and bone formation occurs with osteoid secretion and subsequent
mineralization (Grol et al., 2009).

Bone formation occurs over a period of about 4-6

months (Baron, 2003).
Bone homeostasis is regulated by differential gene expression in bone cells. Local and
systemic factors regulate bone cell activity by activating specific intracellular signaling
pathways. Once exogenous signals have been identified by receptors bound to the cell
membrane, activation of the receptor and subsequent transduction of the signal to the
cell’s nucleus occurs. In the cell nucleus, transcription factor complexes bind to specific
DNA promotor sequences, resulting in the expression of specific genes.
Several signal transduction pathways have been implicated in bone formation.

For

instance, the Ca2+-NFAT signaling pathway has been shown to regulate osteoclast
formation (Boyle et al., 2003, Novack and Teitelbaum, 2008; Teitelbaum and Ross,
2003). In addition, this pathway has a significant role in the regulation of osteoblast
formation and function (Koga et al., 2005; Sun et al., 2005). The Wnt/β-catenin signaling
pathway is important in maintaining a balance between osteoblast and osteoclast activity.
This pathway induces gene expression to upregulate differentiation of osteoblast
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precursor cells and it increases the OPG to RANKL ratio, thus inhibiting osteoclast
formation (Issack et al., 2008; Kubota et al., 2009).
4

Mechanotransduction and Orthodontic Tooth Movement

Mechanotransduction is the process by which mechanical stimuli are transformed into
cellular responses. For over one hundred years, it has been known that bone remodels in
response to physical forces (Wolff, 1892). Mechanical loading increases bone formation,
resulting in improved skeletal strength. Disuse, conversely, suppresses bone formation
and accelerates bone resorption (Duncan and Turner, 1995; Robling et al., 2006). More
recently, research has shown that mechanotransduction involves nucleotide release and
downstream P2 receptor activation (Robling et al, 2006; Dixon and Sims, 2000).
Osteoblasts and osteocytes, communicating via gap junctions, may act as sensors of these
mechanical signals to initiate bone remodeling.

While the exact mechanism of

mechanotransduction is poorly understood, it is known that mechanical strain contributes
to alterations in gene expression (Robling et al., 2006). It is thought that mechanical
loading causes bending in bone and stimulates ATP release from osteoblasts, osteoclasts
and osteocytes. ATP binds to P2 purinergic receptors on the cell surface of bone cells to
initiate signaling that results in osteoclastogenesis and osteoblast differentiation to
stimulate bone remodeling (Robling et al., 2006).
Orthodontic tooth movement is made possible by skeletal mechanotransduction.
Orthodontic forces induce cells in the periodontal ligament and alveolar bone to release
signals that stimulate bone remodeling via alterations in gene expression (Krishnan and
Davidovitch, 2006).

Since mechanotransduction involves nucleotide release and

activation of purinergic receptors, these may have important effects on orthodontic tooth
movement.
5

P2 Receptors

P2 receptors are a group of cellular receptors that bind extracellular nucleotide
messengers, such as ATP and ADP. The P2 receptors are subdivided into P2X and P2Y
receptors based on their mechanism of activation and structural differences (Burnstock,
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1976; Burnstock and Kennedy, 1985; Burnstock, 2004; Burnstock, 2007). P2X receptors
are ATP-gated ion channels (non-selective for Na+, K+ and Ca2+). Adenine nucleotide
binding activates these receptors and leads to membrane depolarization and influx of
intracellular Ca2+.

There are seven types of P2X receptors (P2X1-P2X7) that are

differentially expressed in multiple cell types, including both peripheral and central
neurons, smooth muscle cells and neuroendocrine cells (Dixon and Sims, 2000). The
eight receptors in the P2Y family of receptors (P2Y1, 2, 4, 6, 11-14) are G proteincoupled receptors that are activated by adenine and/or uridine nucleotides (Dixon and
Sims, 2000).
ATP is released from numerous cell types, including osteoblasts, in response to
mechanical disturbance and hypoxia (Bodin and Burnstock, 2001; Lazarowski et al.,
2011; Lazarowski, 2012). Released nucleotides may act in an autocrine or paracrine
manner to influence local P2 receptor signaling (Orriss et al., 2012).

Furthermore,

nucleotide signaling through P2 receptors may be responsible for mechanotransduction in
bone remodeling (Burnstock, 2004; Orriss et al., 2010).
The function of extracellular nucleotides in regulating osteoblastic activity is unclear
(Dixon and Sims, 2000). ATP has been found to stimulate proliferation of murine
calvarial cells, MC3T3-E1 (Suzuki et al., 1993). Additionally, in MC3T3-E1 cells, ATP
has been shown to activate phospholipase A2 (PLA2) (Suzuki et al., 1995; Panupinthu et
al., 2007; Panupinthu et al., 2008), contributing to metabolism of arachidonic acid and the
subsequent production of prostaglandin E2 (PGE2) (Watanabe-Tomita et al., 1997).
The elevation of cytosolic free Ca2+ concentration in osteoblasts has been implicated in
the initial signaling events leading to stimulation of osteoclastic activity (Guggino et al.,
1989). In addition, our lab has shown that nucleotides may act on cells of the osteoblast
lineage to enhance the resorptive actions of PTH (Dixon and Sims, 2000).
Both P2X and P2Y receptors have also been identified on osteoclasts. Activation of
these receptors through nucleotide binding has shown to increase osteoclast activity
(Morrison et al., 1998). In addition, nucleotides regulate osteoclast numbers through the
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induction of apoptosis as a result of the activation of the P2X7 receptor (Dixon and Sims,
2000).
5.1

P2X7 Receptor

The P2X7 receptor is unique among P2X receptors in both its structure and the fact that it
requires a 10-fold higher concentration of ATP (>100 µM) to be activated. Of the P2X
family, the P2X7 receptor is the largest, with a length of 595 amino acids. It contains two
hydrophobic membrane-spanning regions separated by a long glycosylated extracellular
ATP-binding domain (Suprenant et al., 1996; Chessell et al., 2005). The P2X7R also has
a long cytoplasmic C-terminal tail, responsible for mediating its interaction with other
proteins (North, 2002). Whereas ATP is the most potent agonist of other P2XR subtypes,
2’,3’-O-(4-benzoylbenzoyl) ATP (BzATP) is a more potent agonist of the P2X7 receptor
than ATP (Jacobson et al., 2002).
The P2X7 receptor is an ATP-gated ionotropic channel that plays an important role in
inflammation, pain and bone adaptation responses (Volonte et al., 2012; Chessell et al.,
2005; Lister et al., 2007; North, 2002; Labasi et al., 2002; Grol et al., 2009). P2X7
become active (opens) after binding extracellular ATP, which can be released from
adjacent cells under mechanical strain (Bodin and Burnstock, 1998). Initial activation of
P2X7 receptors by ATP leads to an opening of non-selective cation channels, resulting in
an influx of Ca2+ and Na+ and an efflux of K+. Prolonged activation of P2X7 with ATP
leads to large pore formation that allows for passage of large hydrophilic molecules
within seconds (North, 2002). ATP activation also induces downstream signaling events,
which are dependent upon cell type, extracellular conditions and the concentration of
extracellular ATP (Burnstock, 2007).
In humans, several genetic differences in the P2X7 receptor exist and these can affect
channel function. Single nucleotide polymorphisms (SNPs) of the P2X7 receptor have
been identified to be associated with various musculoskeletal, inflammatory and
cardiovascular diseases (Jiang et al., 2013). Among the effects of loss of function in
P2X7 is enhanced loss of bone mineral density in post-menopausal women (Gartland et
al., 2012).

Furthermore, variability in function of the P2X7 receptor may explain
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individual differences in response to orthodontic forces and may explain why some
individuals are susceptible to root resorption (Viecilli et al., 2009; Hartsfield, 2009).
Key mediators of inflammation, such as PGE2, IL-1α, and IL-1β are released in response
to P2X7 activation.

All of these factors are critical in the maintenance of bone

physiology (Ferrari et al., 2006; Li et al., 2005). The release of cytokines, in turn, can
induce accumulation of neutrophils and lymphocytes (Chen and Brosnan, 2006).
Neutrophils further assist in mediating the inflammatory response by acting to eliminate
apoptotic cells from the site and prevent further necrosis. Labasi et al. showed that
murine macrophages deficient in P2rx7 (the gene encoding P2X7) do not release IL-1 in
response to stimulation with ATP, resulting in an attenuated acute inflammatory response
(Labasi et al., 2002).
Due to the role of P2X7 in mediating inflammatory pain, several pharmaceutical
companies have initiated a search for selective P2X7 receptor antagonists. Systematic
administration of the selective P2X7 antagonist A438079 reduces thermal hyperalgesia
(Nelsen et al., 2006; Donnelly-Roberts and Jarvis, 2007). Progress made recent years
strongly suggests that receptor-specific P2X antagonists may be useful analgesics in
humans. Additionally, such drugs may modulate bone remodeling, such as in orthodontic
tooth movement.
Investigating P2rx7 knockout (KO) mice has provided significant insight into this
receptor’s role in mechanotransduction. P2X7-deficient mice have reduced sensitivity to
mechanical loading due to decreased secretion of PGE2 (Li et al., 2005). Viecilli et al.
found that lack of the P2X7 contributed to slower removal of hyalinized tissue in P2rx7
KO mice.

In addition, these KO mice exhibited increased rates of external root

resorption in orthodontically moved teeth (Viecilli et al., 2009). Furthermore, P2X7 KO
mice also show decreased periosteal bone formation and increased trabecular bone
resorption (Ke et al., 2003). Collectively, these findings suggest that P2X7 may be
necessary for skeletal growth and may contribute to physiologic balance between bone
formation and resorption in response to mechanical force. Clearly the P2X7 receptor is
an ideal candidate for mediating orthodontic responses, which involve both the induction
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of an acute inflammatory response and bone remodeling (Roberts, 1989; Reitan, 1994;
Roberts et al., 2004).
A number of cell-type specific signaling pathways are associated with P2X7 receptor
activation. Because these pathways are cell-specific, it appears that in each cell type
P2X7 has unique downstream signaling effects.
5.1.1

P2X7 Receptor Signaling in Osteoblasts

ATP and BzATP induce opening of the P2X7 non-selective cation channel, leading to an
increase in intracellular Ca2+. This then couples to multiple signaling pathways in cells
of the osteoblast lineage (Grol et al., 2009).
First, P2X7 receptors have been shown to mediate extracellular signal-regulated kinase
(ERK) 1/2 activation by fluid shear stress in an osteoblast-like cell line (Liu et al., 2008).
ERK activation by fluid flow was found to stimulate expression of various osteogenic
genes including: osteopontin (OPN), c-Fos, cyclooxygenase-2 (COX-2), collagen type I,
and cbfa1/RUNX2 (You et al., 2001; Okumura et al., 2008; Wadhwa et al., 2002;
Mehrotra et al., 2006). Furthermore, Rubin et al. (2003) found that physiologic levels of
mechanical strain utilized ERK 1/2 kinase to regulate production of NO and RANKL in a
manner that promotes net bone formation (Rubin et al., 2003).
Second, the P2X7 receptor is responsible for fluid shear-stress-induced activation of the
transcription factor nuclear factor kappa-B (NF-κB) (Genetos et al., 2011). MC3T3-E1
osteoblasts express the NF-κB inhibitory protein IκBα under static conditions. Under
fluid shear stress, IκBα levels decreased and nuclear localization and expression of NFκB occurs. Genetos et al. showed that P2X7R-mediated activation of NF-κB occurs
independently of lysophosphatidic acid (LPA) signaling. Chen and Brosnan demonstrated
that prostaglandin E2 (PGE2) release requires purinergic signaling and that the NF-κB is
required for maximal cyclooxygenase-2 (COX-2) induction in response to fluid shear
stress (Chen and Brosnan, 2006).
Third, Panupinthu et al. reported that P2X7 receptors signal though phospholipase D
(PLD) and phospholipase A2 (PLA2). Two products are the result of PLD and PLA2
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activity: lysophosphatidic acid (LPA) and arachidonic acid.

Arachidonic acid is

metabolized to PGs and other eicosanoids. LPA acts on its receptors on osteoblasts to
cause membrane blebbing via a pathway dependent on Rho-associated kinase. The
P2X7-LPA-PG axis is thought to be of significance to P2X7-mediated osteogenesis
during mechanotransduction (Figure 1). Panupinthu et al. proposed that mechanical
stimuli induce release of ATP, which then acts through P2X7 receptors on osteoblasts,
leading to the production of prostaglandins and LPA. Prostaglandins and LPA then act in
an autocrine or paracrine manner to enhance bone formation, explaining the role of the
P2X7 receptors in skeletal development and mechanotransduction (Panupinthu et al.,
2007; Panupinthu et al., 2008).
Dr. Na (Na, 2016) investigated the effects of dexamethasone, a corticosteroid with antiinflammatory effects, on gene expression in MC3T3-E1 cells following P2X7 receptor
activation with BzATP. She showed that BzATP stimulation of genes Ptgs2 and Dmp1
was inhibited by dexamethasone. This finding further exemplifies the role that P2X7
may play in regulating osteoblast development and eventual bone formation during
orthodontic tooth movement and shows that dexamethasone may inhibit these processes
(Na, 2016).
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Figure 1. Proposed P2X7-LPA/PG signaling axis promoting osteogenesis.
Activation of P2X7 by endogenous ATP or exogenous BzATP leads to production of
lysophosphatidic acid (LPA) and prostaglandin (PG).

LPA is synthesized from

membrane lipids following the activation of phospholipase D (PLD) and phospholipase
A2 (PLA2). Activation of PLA2 also leads to the production of arachidonic acid that is
converted to PGs by the action of cyclooxygenase (COX). LPA and PG may act in an
autocrine or paracrine manner to induce expression of anabolic genes and subsequently
promote osteoblast differentiation and mineralization (osteogenesis). Image modified
with permission from Panupinthu et al., 2008.
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5.1.2

P2X7 signaling in osteoclasts

Initial studies revealed that P2X7 may be involved in osteoclast fusion and up-regulating
osteoclast differentiation (Gartland et al., 2003). However, further investigation into
P2X7R KO mice revealed that P2X7 in osteoclasts has a role in initiating apoptosis and
thus inhibits osteoclast-induced bone resorption (Ke et al., 2003; Grol et al., 2009).
These conflicting results have led to the explanation that the timing and degree of P2X7
receptor activation may govern its effects on osteoclasts.

Figure 2. Effects of ATP stimulation of P2X7 receptors in osteoblasts and
osteoclasts.
This figure illustrates potential roles for P2X7 signaling in osteoblasts and osteoclasts.
Nucleotides, including ATP, released from osteoblasts in response to mechanical
stimulation signal through P2 receptors to mediate bone remodeling. P2X7 activation in
osteoblasts results in bone formation, whereas its activation in osteoclasts promotes
apoptosis. Image reprinted with permission from Purinergic Signaling, Grol et al., 2009;
Appendix B.
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6

Lysophosphatidic Acid

Lysophosphatidic acid (LPA) is a potent bioactive phospholipid produced by several
cells such as activated platelets.

LPA is present in low levels in the plasma under

resting conditions and becomes elevated in inflammation and tissue injury. LPA acts on
six G protein-coupled receptors (LPA1-6) (Yung et al., 2014; Sheng et al., 2015).
Activation of LPA receptors can lead to elevation of intracellular Ca2+ concentration,
activation of ERK and stimulation of phosphatidylinositol 3-kinase signaling (PI3K)
(Sims et al., 2013). LPA is also involved in regulating cell migration and chemotaxis
(Sugimoto et al., 2006).
LPA induces the production of cytokines in osteoblasts, which are known to regulate
osteoclast function. Our lab has shown that osteoblasts produce LPA, which may be
involved in the pathogenesis of bone diseases, such as in rheumatoid arthritis (Sims et
al., 2013). Activation of P2X7 receptors on osteoblasts leads to the production of LPA,
through the sequential activation of PLD and PLA2. LPA may act on osteoblasts in an
autocrine manner to regulate osteoblastic activity. Osteoblast-derived LPA may also act
in a paracrine manner to regulate osteoclasts (Sims et al., 2013).
LPA has a stimulatory effect on osteoclastogenesis. However, it is not known if this
effect is direct or if LPA affects other cell types that may in turn alter osteoclast
behavior. Lapierre et al. showed that LPA enhances the survival of osteoclasts in vitro,
promotes their fusion and suppresses their apoptosis (Lapierre et al., 2010). LPA acts
though several receptor types on osteoclasts to induce an increase in intracellular Ca2+
and activate the critical transcription factor NFATc1, which is associated with RANKLstimulated osteoclast differentiation (Pereverzev et al., 2008). LPA also has a direct
effect on osteoclast motility, specifically by retraction of osteoclast pseudopodia
(Lapierre et al, 2010). Effects of LPA on osteoclast resorption has produced conflicting
results, as some studies have shown a slight decrease in resorption by osteoclasts
(Lapierre et al, 2010) and others have shown an increase (McMichael et al., 2010).
In summary, LPA may be partly responsible for the coordination of osteoblast and
osteoclast activity in bone.

Nucleotide signaling through the P2X7 receptors and
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subsequent production of LPA reveals a new signaling axis that may play a role in
skeletal mechanotransduction.

In addition to the physiological roles LPA plays in

regulation of osteoblast and osteoclast activity, LPA may contribute to the progression
of bone diseases.
7

Prostaglandins

Prostaglandins (PGs) are important regulators in the inflammatory response and skeletal
metabolism. PGs are lipids that stimulate G protein-coupled receptors in multiple areas
of the body in an autocrine or paracrine manner. PGE2 is produced in response to several
factors that regulate bone metabolism, such as growth factors (PDGF), hormones (PTH)
and interleukins (Flanagan and Chambers, 1992; Blackwell et al., 2010).
There are three major steps in the production of PGs such as PGE2; each are subject to
regulation and each step can be rate limiting (Figure 3). First, phospholipids (PL) are
metabolized to arachidonic acid at the cell membrane, through the enzymatic action of
PLA2.

Second is the conversion of arachidonic acid to PGH2 by cyclooxygenase

(COX), also known as prostaglandin-endoperoxide synthase (PTGS).

COX is

responsible for the formation of prostanoids, such as thromboxane and prostaglandins
(Blackwell et al., 2010). Two types of COX enzymes exist: COX-1 and COX-2. The
gene encoding COX-1 (PTGS1) is constitutively expressed and COX-1 responsible for
protecting

the

gastrointestinal

mucosa,

kidney

hemodynamics

and

platelet

thrombogenesis. On the other hand, the gene encoding COX-2 (PTGS2) is expressed at
low levels under basal conditions and is rapidly induced in response to inflammation
(Rouzer and Marnett, 2009).
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Figure 3: Conversion of phospholipids to prostaglandin (PGE2).
Membrane phospholipids (PL) are metabolized by PLA2 to arachidonic acid (AA). This
action is inhibited through the action of corticosteroids, such as dexamethasone. COX
metabolizes AA to prostaglandin H2 (PGH2). Non-steroidal anti-inflammatory drugs
(NSAIDs), such as ibuprofen, inhibit COX.

Next, prostaglandin E synthase (PGE

synthase) metabolizes PGH2 further into PGE2, as shown above.

In bone, PGs play a role in remodeling by stimulating both resorption and formation.
Application of an orthodontic force induces the production of PGs, which induces
alveolar bone remodeling to promote tooth movement (Davidovitch et al., 1988; Lee,
1990; Leiker et al., 1995). Local injection of PG into the paradental tissues of rodents
causes an increase in osteoclast numbers (Yamasaki et al., 1984). Reduction in the rate
of orthodontic tooth movement has been shown with administration of non-specific
COX inhibitors, such as indomethacin (Chumbley and Tuncay, 1986). The increase in
bone resorption observed with addition of PGE2 is thought to occur via an upregulation
of receptor activator of NF-κB ligand (RANKL) expression and inhibition of
osteoprotegerin (OPG) expression in osteoblast cells (Blackwell et al., 2010).
Furthermore, PGE2 is thought to stimulate cells to produce the intracellular second
messenger, cAMP, which is an important regulator for bone resorption (Klein, 1970;
Raisz et al., 1974). Although PGE2 was initially recognized for its effects on bone
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resorption, it became evident that it also stimulates bone formation. Similar to PTH,
continuous administration of PGE2 has shown to have resorptive effects on bone,
whereas intermittent administration is anabolic (Tian et al., 2008). PGE2 stimulates
osteoblastic differentiation in murine marrow stromal cell cultures deficient in
endogenous PG due to deletion of Ptgs2 (Zhang et al., 2012).
Elevated PG production associated with inflammatory diseases, such as rheumatoid
arthritis, can cause bone loss. Selective inhibition of COX-2 can reduce bone loss
associated with inflammatory joints in rodent models (Anderson et al, 2009) and can
reduce osteoclast numbers (Taketa et al., 2008).
PGs are thought to induce bone formation in response to mechanical loading and stress
(Blackwell et al., 2010).

Numerous studies have shown that mechanical loading

increases production of COX-2 and PGs. Inhibition of COX by non-steroidal antiinflammatory drugs (NSAIDs) has been shown to have an inhibitory effect on bone
formation in response to loading (Blackwell et al., 2010). Recent work in our lab has
shown that activation of P2X7 stimulates expression of Ptgs2 (COX-2) in osteoblasts
within 3 hours of BzATP treatment (Grol et al., 2013; Na, 2016).
8

Rationale, Hypothesis and Objectives of the Research

Since purinergic signaling is known to be important in osteoblast differentiation and
function, the aim of this project was to further investigate the signal transduction
pathways that operate downstream of P2 receptor activation in cells of the osteoblast
lineage.
Objective 1: To determine if P2X7 is the receptor activated by BzATP to induce
anabolic gene expression by osteoblasts.
Previous studies by Dr. Na showed that BzATP induced anabolic gene expression by
osteoblasts (Na, 2016); however, the receptor(s) mediating this effect were not
identified. Considering the important role that P2X7 plays in mechanotransduction, we
hypothesized that P2X7 is the receptor responsible for inducing anabolic gene
expression. To test this hypothesis, we used a specific antagonist to P2X7 receptor,
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A438079, and examined its effects on BzATP-induced expression of the anabolic genes
(Ptgs2, Dmp1, c-Fos) (Figure 4).
Objective 2: To investigate the role of the PG and LPA signaling pathways in
mediating the effects of BzATP on anabolic gene expression by osteoblasts.
Previous studies in our lab by Panupinthu et al. showed that P2X7 activation in
osteoblasts led to rapid production of the lipid mediators PGE2 and LPA (Panupinthu et
al., 2007; Panupinthu et al., 2008).

Moreover, Dr. Na investigated the effects of

dexamethasone (Na, 2016), which is known to suppress PLA2 activity and therefore
block production of both PGE2 and LPA. Dr. Na found that dexamethasone abolished
the effects of BzATP on Ptgs2 and Dmp1 expression, consistent with the possible
involvement of PGE2 and/or LPA. Therefore, we hypothesized that PGE2 and/or LPA
mediate the stimulatory effect of BzATP on Ptgs2 expression.
We first assessed whether PG, LPA or both are necessary for inducing expression of
Ptgs2. We used a COX inhibitor (that blocks PG synthesis) and/or an LPA receptor
antagonist to assess the effect of loss of PG and LPA signaling on BzATP-induced gene
expression (Figure 5). Next, we assessed whether PGE2, LPA or both are sufficient for
inducing expression of Ptgs2 in osteoblastic cells. To do this, we introduced PGE2
and/or LPA (in the absence of exogenous nucleotides) and assessed their effect on Ptgs2
expression (Figure 6).
In achieving the above objectives, we hoped to gain insight on how each of these
elements influences gene expression in osteoblastic cells (Figure 7).
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Figure 4: Schematic showing the potential effects of a P2X7 antagonist, A438079,
on BzATP-induced gene expression at the P2X7 receptor.

BzATP has previously been shown to induce anabolic gene expression in MC3T3-E1
cells (Na, 2016). Since BzATP is an agonist for multiple P2 receptors, it is not known if
P2X7 is the receptor responsible for inducing anabolic gene expression. Using a P2X7
specific antagonist, A438079, we aimed to clarify the role of P2X7 in mediating
BzATP-induced gene expression in MC3T3-E1 cells.
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Figure 5: Investigating the roles that PG and LPA may play downstream of P2X7
receptor activation.

In using ibuprofen (IBP), a COX inhibitor, we examined the effects of BzATP on gene
expression in the absence of PGs. Similarly, using an LPA receptor antagonist, VPC32183, we explored the role of LPA in P2X7-driven Ptgs2 gene expression in MC3T3E1 cells.
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Figure 6: Effect of PG (PGE2) and LPA on gene expression in osteoblastic cells.
By exposing MC3T3-E1 cells directly to PG, LPA or a combination of the two
mediators, we assessed their individual or combined effects on Ptgs2 gene expression.
No exogenous nucleotides were added in these experiments.
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Figure 7: The proposed P2X7-PG-LPA axis and its effects on gene expression in
osteoblast precursor cells.
At least three pathways are activated by P2X7 stimulation in osteoblastic cells by
endogenous ATP or exogenous BzATP. First, activation of P2X7 leads to formation of
prostaglandin (PG).

Second, activation of P2X7 leads to production of

lysophosphatidic acid (LPA). PG and LPA then bind to their receptors (PGR and
LPAR) on the same or adjacent cells to induce gene expression. Lastly, P2X7 may act
through additional pathway(s) to regulate gene expression (centre arrow). Our overall
objective was to explore which of these three pathways or combinations thereof, are
important for anabolic gene expression in osteoblasts.
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MATERIALS AND METHODS
1

Materials and Solutions

α-Minimum essential medium (α-MEM), heat-inactivated fetal bovine serum (FBS),
antibiotic solution (10,000 U/ml penicillin, 10,000 mg/ml streptomycin, and 25 mg/ ml
amphotericin B), trypsin solution, Dulbecco’s phosphate-buffered saline (DPBS) were
obtained from GIBCO (Life Technologies Inc., Burlington, ON, Canada). TRIzol
reagent and UltraPure distilled water (DNase/RNase-free) were obtained from
Invitrogen (Life Technologies). RNeasy Mini Kit was from QIAGEN (Toronto, ON,
Canada). qScript XLT One-Step RTqPCR Toughmix was purchased from Quanta.
Primers and probes for Ptgs2 (COX2, Mm00478374_m1), Dmp1 (Mm01208363_m1),
c-Fos (Mm00487425_m1), and 18S rRNA were obtained from Applied Biosystems
(Life

Technologies).

2’-3’-O-(4-benzoylbenzoyl)

adenosine

5’-triphosphate

triethylammonium salt (BzATP) and lysophosphatidic acid (LPA) was obtained from
Sigma-Aldrich (St. Louis, MO, USA). Ibuprofen, A438079 and PGE2 were obtained
from Tocris Bioscience (Bristol, UK).

VPC-32183 was from Avanti Polar Lipids

(Alabaster, AL, USA).
2

Cell Culture

A mouse calvarial pre-osteoblast cell line, MC3T3-E1 (subclone 4), was obtained from
the American Type Culture Collection (Rockville, MD, USA). These cells were cultured
every 72 hours and maintained in α-MEM, supplemented with 10% FBS and 1%
antibiotic solution (culture medium) at 37C and 5% CO2.
3

RNA Isolation

TRIZOL® reagent (Invitrogen, Paisley, UK) and RNeasy were used to extract total
RNA, according to the manufacturer's instructions.

Quantification of RNA was

determined spectrophotometrically by measuring absorbance at 260 nm. In order to
normalize RNA samples, the RNA was diluted to a final concentration of 25 ng/l in
RNase free water and was stored at −80 °C until amplification by Real-Time RT-PCR.
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4

Real-Time RT-PCR Analyses

In the first series of experiments (Objective 1), MC3T3-E1 cells were plated at a density
of 1.5x104 cells/cm2 on Falcon 6-well plates in supplemented culture medium. After 48
hours, cells were placed in serum-free medium and incubated overnight. On the day of
the experiment, cells were pretreated with A438079 (10 M) or its vehicle (ddH20) for
20 minutes. After 20 minutes (t = 0), BzATP (300 M) or its vehicle (divalent cation
free buffer, DCFB) was added and the cells were incubated for the indicated times (0,
0.5, 1 and 3 hours) (Figure 8). Total RNA was then isolated from each sample as
mentioned above. Real-time PCR, using the ABI Prism 7900 HT Sequence Detector
(PerkinElmer), was performed with a 15 L final reaction volumes containing 25 ng
RNA sample, qScript XLT One-Step RTqPCR Toughmix, and one of Ptgs2, c-Fos,
Dmp1, or 18S rRNA primers and probes. Reverse transcription was performed at 50 °C
for 10 min followed by 40 cycles of amplification at an annealing temperature of 60 °C.
Reactions for each sample were performed in triplicate. All samples were normalized to
18S rRNA, and time zero or vehicle-treated controls using the delta-delta cycle
threshold (Ct) method.
In the second series of experiments (Objective 2a), MC3T3-E1 cells were plated at a
density of 1.5x104 cells/cm2 on Falcon 6-well plates in culture medium. After 48 hours,
cells were placed in serum-free medium and incubated overnight. On the day of the
experiment, cells were pretreated with ibuprofen (10 M) or its vehicle (DMSO) and
VPC-32183 (1 M) or its vehicle (3% BSA) for 20 minutes. After 20 minutes (t = 0),
cells were incubated with BzATP (300 M) or its vehicle (divalent cation-free buffer,
DCFB) and total RNA was isolated as mentioned above (Figure 9). Real-time PCR was
performed to assess Ptgs2 gene expression using the techniques previously mentioned
and samples were normalized using the Ct method.
In the third series of experiments (Objective 2b), MC3T3-E1 cells were plated at a
density of 1.5x104 cells/cm2 on Falcon 6-well plates in culture medium. After 48 hours,
cells were placed in serum-free medium and incubated overnight. On the day of the
experiment, cells were incubated with PGE2 (1 M) or its vehicle (DMSO) and LPA (1
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M) or its vehicle (3% BSA) for three hours and RNA was isolated as previously
described (Figure 10).

Real-time PCR was completed as previously described,

examining Ptgs2 gene expression in each sample. Again, reactions for each sample
were performed in triplicate. All samples were normalized to 18S rRNA, and time zero
or vehicle-treated controls using the delta-delta cycle threshold (Ct) method.
5

Statistical Analysis

Data are shown as means ± standard error of the mean (SEM) for the number (n) of
experiments indicated, each performed in triplicate. Differences among three or more
groups were evaluated by one-way or two-way analysis of variance (ANOVA) followed
by a Bonferroni post hoc multiple comparisons test. Differences were accepted as
statistically significant at p < 0.05. Data analysis was performed using GraphPad Prism
6.0 (GraphPad Software, San Diego, CA).
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Figure 8. Timeline of the first series of experiments.
A) MC3T3-E1 cells were plated at a density of 1.5x104 cells/cm2 in Falcon 6-well plates
in culture medium (day 0). After 2 days, cells were placed in serum-free medium.
B) On the day of the experiment (day 3), cells were pretreated with A438079 (10 M) or
its vehicle (ddH20) for 20 minutes. After 20 minutes (t = 0), BzATP (300 M) or its
vehicle (DCFB) was added. Total RNA was then isolated using Trizol at 0, 0.5, 1, and 3
hours.
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Figure 9. Timeline of the second series of experiments.
A) MC3T3-E1 cells were plated at a density of 1.5x104 cells/cm2 in Falcon 6-well plates
in culture medium (day 0). After 2 days, cells were placed in serum-free medium.
B) On the day of the experiment (day 3), cells were incubated with ibuprofen (10 μM) or
its vehicle (DMSO) and VPC-32183 (1 μM) or its vehicle (3% BSA) for 20 minutes. At
time 0, BzATP (300 μM) or its vehicle (DCFB) was added in the continued presence of
ibuprofen, VPC-32183 or vehicle. Total RNA was then isolated using Trizol at 3 hours.
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Figure 10. Timeline of the third series of experiments.
A) MC3T3-E1 cells were plated at a density of 1.5x104 cells/cm2 in Falcon 6-well plates
in culture medium (day 0). After 2 days, cells were placed in serum-free medium.
B) On the day of the experiment (day 3), cells were incubated with PGE2 (1 μM) or its
vehicle (DMSO) and LPA (1 μM) or its vehicle (3% BSA) for 3 hours. Total RNA was
then isolated using Trizol at 3 hours.
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RESULTS

1

BzATP-induced stimulation of Ptgs2 (COX-2) expression was inhibited by the

P2X7 antagonist, A438079
Ptgs2 encodes prostaglandin-endoperoxide synthase 2, also known as cyclooxygenase-2
(COX-2), which mediates the synthesis of PGs (Blackwell et al., 2010).

Changes in Ptgs2 expression were examined in MC3T3-E1 cells following treatment
with vehicle (DCF Buffer) or BzATP (300 μM) in the presence or absence of the
specific P2X7 antagonist, A438079 (10 μM). Similar to results previously shown in our
lab (Grol et al., 2013), BzATP induced peak Ptgs2 expression at three hours (342  52
fold increase relative to vehicle-treated cultures at time 0) (Figure 11, blue). Significant
Ptgs2 expression (320  47 fold) was also observed at one hour, a similar time point to
previous studies done in our lab (Na, 2016). BzATP had a significant effect on Ptgs2
gene expression at both 1 and 3 h (p < 0.05). A438079 alone did not significantly affect
Ptgs2 expression; however, A438079 significantly blocked BzATP-induced Ptgs2
expression at 1 h and 3 h (p < 0.05) (Figure 11, green). Taken together, these data
indicate that P2X7 is the receptor responsible for BzATP-induced Ptgs2 expression in
MC3T3-E1 cells.
2

BzATP-induced stimulation of Dmp1 expression was inhibited by A438079

Dmp1 encodes dentin matrix acidic phosphoprotein 1, which is present bone and dentin,
and has been shown to be necessary for their mineralization (George et al., 1993;
MacDougall et al., 1998; Feng et al., 2006). Bone cells, including osteocytes and
osteoblasts, express Dmp1 (Feng et al., 2003; Toyosawa et al., 2012).

BzATP

stimulation of Dmp1 expression, which was greatest at 3 h (6070  2014 fold increase),
was completely inhibited by treatment with A438079 (p < 0.05) (Figure 12, compare
blue and green lines). Maximal expression of Dmp1 at 3 hours was consistent with
previous findings in our lab (Na, 2016).
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3

BzATP-induced stimulation of c-Fos expression was inhibited by A438079

c-Fos is an immediate early gene, which has been implicated in osteoblast proliferation,
differentiation and survival (Dixon and Sims, 2000). In osteoblast precursor cells, FOS
protein expression is high during proliferation, but levels decline during further
maturation and differentiation (McCabe et al., 1995).
Significant c-Fos expression was seen at 30 minutes (63  21 fold) and one hour (67 
18) following BzATP stimulation (Figure 13, blue). Expression was transient, returning
to a basal level by 3 hours. Similar results were seen previously in our lab with peak cFos expression seen at 30 minutes (Na, 2016).

Again, treatment with A438079

completely inhibited c-Fos expression induced by BzATP (Figure 13, green) (p < 0.05).
Thus, the effects of BzATP on expression of Ptgs2, Dmp1 and c-Fos appear to be
mediated by P2X7.
4

BzATP-induced stimulation of Ptgs2 expression was inhibited by treatment with

VPC-32183 and ibuprofen
For Objective 2, we chose to focus our studies on Ptgs2 expression for several reasons.
First, COX-2 inhibitors have received an abundance of attention in recent years with
respect to their effects on bone healing and remodeling, and their possible actions on
orthodontic tooth movement (Cottrell and O-Connor, 2010; Fang et al, 2016; Proffit,
2012). Additionally, we had previously observed dramatic stimulation of Ptgs2 in
response to BzATP stimulation in osteoblastic cells (Grol et al., 2013; Na, 2016).

Ibuprofen is a non-selective inhibitor for COX.

At the 3 h time point, ibuprofen

significantly reduced BzATP-induced expression of Ptgs2 (p < 0.05) (Figure 14).

VPC-32183 is a selective antagonist of LPA receptors LPA1 and LPA3 (Heasley, 2004).
In MC3T3-E1 cells, the LPA1 receptor is the most abundant receptor for LPA, with
LPA3 expression virtually undetectable (Masiello et al., 2006). When MC3T3-E1 cells
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were harvested at 3 h, VPC-32183 significantly reduced BzATP induced expression of
Ptgs2 (p < 0.05) (Figure 14).

The combined effect of VPC-32183 and ibuprofen on MC3T3-E1 cells at 3 hours was
virtually complete inhibition of Ptgs2 expression (p < 0.05) (Figure 14). Thus, both PG
and LPA signaling appear to be necessary for mediating the effects of P2X7 activation
on Ptgs2 expression.
5

PGE2 and LPA had a synergistic stimulatory effect on Ptgs2 gene expression in

MC3T3-E1 cells
Previously published dose-response data for both PGE2 (Suda et al., 1998) and LPA
(Nochi et al., 2008) led us to select 1 M concentrations for both factors, as this
concentration resulted in maximum anabolic gene expression in osteoblastic cells.
Interestingly, in our experiments, PGE2 or LPA alone did not significantly stimulate
Ptgs2 gene expression in MC3T3-E1 cells. However, their combined effect was a
significant increase in Ptgs2 expression after 3 h of incubation (739  500 fold
compared to vehicle-treated cultures, p < 0.05, Figure 15). Thus, in combination, PGE2
and LPA appear to be sufficient to mimic the effect of P2X7 activation on Ptgs2
expression.

NB: Please refer to Appendix A for data presented as relative gene expression without
normalization as percentage of the maximum value.
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Figure 11: BzATP-induced stimulation of Ptgs2 expression was completely
inhibited by the P2X7 antagonist A438079.
MC3T3-E1 cells were pretreated with A438079 (10 M) or its vehicle for 20 minutes
and then incubated with BzATP (300 μM) or its vehicle at time 0 (in the continued
presence of A438079 or its vehicle). Total RNA was isolated at the indicated times.
Real-time RT-PCR was performed to assess expression of Ptgs2. Data were normalized
to levels of 18S ribosomal RNA, and relative to values for vehicle-treated cultures at
time 0. Data are shown as percentages of the maximum value in each individual
experiment and are presented as means ± S.E.M. (n = 3 independent experiments, each
performed in triplicate). The mean maximum value (100%) for these 3 experiments was
342 ± 52 fold increase relative to vehicle-treated cultures at time 0. Data were analyzed
by two-way ANOVA followed by a Bonferroni post hoc multiple comparisons test. 
indicates a significant difference between BzATP and vehicle at each time point; 
indicates a significant effect of the P2X7 antagonist, A438079; p < 0.05.
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Figure 12: BzATP-induced stimulation of Dmp1 expression was completely
inhibited by A438079.
MC3T3-E1 cells were pretreated with A438079 (10 M) or its vehicle for 20 minutes
and then incubated with BzATP (300 μM) or its vehicle at time 0 (in the continued
presence of A438079 or its vehicle). Total RNA was isolated at the indicated times.
Real-time RT-PCR was performed to assess expression levels of Dmp1. Data were
normalized to levels of 18S ribosomal RNA, and relative to values for vehicle-treated
cultures at time 0. Data are shown as percentages of the maximum value in each
individual experiment and are presented as means ± S.E.M. (n = 3 independent
experiments, each performed in triplicate). The mean maximum value (100%) for these
3 experiments was 6070 ± 2014 fold increase relative to vehicle-treated cultures at time
0. Differences were evaluated by two-way ANOVA followed by a Bonferroni multiple
comparisons test.  indicates a significant difference between BzATP and vehicle at
each time point;  indicates a significant effect of the P2X7 antagonist, A438079; p <
0.05.
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Figure 13: BzATP-induced stimulation of c-Fos expression was completely
inhibited by A438079.
MC3T3-E1 cells were pretreated with A438079 (10 M) or its vehicle for 20 minutes
and then incubated with BzATP (300 μM) or its vehicle at time 0 (in the continued
presence of A438079 or its vehicle). Total RNA was isolated at the indicated times.
Real-time RT-PCR was performed to assess expression levels of c-Fos. Data were
normalized to levels of 18S ribosomal RNA, and relative to values for vehicle-treated
cultures at time 0. Data are shown as percentages of the maximum value in each
individual experiment and are presented as means ± S.E.M. (n = 3 independent
experiments, each performed in triplicate). The mean maximum value (100%) for these
3 experiments was 67 ± 18 fold increase relative to vehicle-treated cultures at time 0.
Differences were evaluated by two-way ANOVA followed by a Bonferroni multiple
comparisons test.  indicates a significant difference between BzATP and vehicle at
each time point;  indicates a significant effect of the P2X7 antagonist, A438079; p <
0.05.
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Figure 14: BzATP-induced stimulation of Ptgs2 expression was inhibited by the
COX inhibitor ibuprofen and the LPA receptor antagonist VPC-32183.
MC3T3-E1 cells were pretreated with ibuprofen (10 μM) or its vehicle (DMSO) and
VPC-32183 (VPC) (1 μM) or its vehicle (3% BSA) for 20 minutes. After 20 minutes,
BzATP (300 M) or its vehicle (DCFB) was added (in the continued presence of
ibuprofen, VPC-32183, or vehicle). Total RNA was isolated at 3 hours for all treatment
groups. Real-time RT-PCR was performed to assess the expression of Ptgs2. Data were
normalized to levels of 18S ribosomal RNA, and relative to values for cultures treated
only with vehicles. Data are shown as percentages of the maximum value in each
individual experiment and are presented as means ± S.E.M. (n = 3 independent
experiments, each performed in triplicate). The mean maximum value (100%) for these
3 experiments was 59 ± 7 fold increase relative to vehicle-treated cultures. Differences
were evaluated by two-way ANOVA followed by a Bonferroni multiple comparisons
test.  indicates a significant difference between BzATP and vehicle at each time point;
 indicates a significant effect of ibuprofen and/or VPC-32183; p < 0.05.
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Figure 15: PGE2 and LPA combined induced Ptgs2 gene expression in MC3T3-E1
cells.
MC3T3-E1 cells were incubated with PGE2 (1 μM) or its vehicle (DMSO) and LPA (1
μM) or its vehicle (3% BSA) at time 0. No exogenous BzATP was added. Total RNA
was isolated at 3 hours for all treatment groups. Real-time RT-PCR was performed to
assess expression levels of Ptgs2. Data were normalized to levels of 18S ribosomal
RNA, and relative to values for vehicle-treated cultures. Data are shown as percentages
of the maximum value in each individual experiment and are presented as means ±
S.E.M. (n = 3 independent experiments, each performed in triplicate). The mean
maximum value (100%) for these 3 experiments was 739  500 fold increase relative to
vehicle-treated cultures at time 0. Differences were evaluated by one-way ANOVA
followed by a Bonferroni multiple comparisons test.  indicates a significant difference
between PGE2, LPA or both and vehicle; p < 0.05.
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DISCUSSION

1

Summary and Conclusions

Objective 1: To determine if P2X7 is the receptor activated by BzATP to induce anabolic
gene expression by osteoblasts.


As shown previously by Dr. Na, BzATP stimulated expression of Ptgs2, Dmp1
and c-Fos. We found that the specific P2X7 antagonist, A438079, inhibited
expression of all three genes. These data indicate that P2X7 is the receptor
activated by BzATP to induce expression of these genes in MC3T3-E1
osteoblastic cells.

Objective 2: To investigate the role of the PG and LPA signaling pathways in mediating
the effects of BzATP on anabolic gene expression by osteoblasts.


BzATP-induced stimulation of Ptgs2 expression was reduced by treatment with
the LPA1/3 receptor antagonist VPC-32183.



BzATP-induced stimulation of Ptgs2 expression was reduced by treatment with
the COX inhibitor ibuprofen.



VPC-32183 and ibuprofen combined abolished Ptgs2 gene expression in
BzATP-stimulated MC3T3-E1 cells.



Individually, PGE2 or LPA had little effect on Ptgs2 gene expression in MC3T3E1 cells.



Combined, PGE2 and LPA displayed a dramatic synergistic effect on Ptgs2 gene
expression.



Taken together, LPA and PG signaling pathways appear to be both necessary and
sufficient to mediate the effect of P2X7 on Ptgs2 expression in MC3T3-E1
osteoblastic cells.
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2

P2X7 regulates expression of anabolic genes

In Objective 1, we aimed to determine if P2X7 is the receptor activated by BzATP that
induces anabolic gene expression in osteoblasts. BzATP is not a specific agonist for the
P2X7 receptor. BzATP has previously been shown to activate a number of other
receptors including P2Y11, P2X1, and P2X4 with similar potency (Bianchi et al., 1999;
Communi et al., 1999; Naemsch et al., 1999; North, 2002). Using a specific P2X7
antagonist, we were able to show that BzATP stimulates expression of Ptgs2, Dmp1 and
c-Fos by activating P2X7.
Previously, Dr. Na examined changes in Ptgs2, Dmp1 and c-Fos expression following
BzATP activation of P2X7 in osteoblastic cells (Na, 2016). Furthermore, Dr. Na showed
that dexamethasone has an inhibitory effect on BzATP-induced expression of Ptgs2 and
Dmp1. Interestingly, Dr. Na found that BzATP-induced expression of c-Fos was not
affected by treatment with dexamethasone, indicating the potential for specificity in
dexamethasone action.
Ptgs2 encodes prostaglandin-endoperoxide synthase-2 (COX-2) and is important for PG
production. PGs are imperative in regulation of bone metabolism, by inducing both
bone formation and resorption, and they are necessary in fracture healing (Blackwell et
al., 2010).

Previous studies have shown that osteoblast mechanotransduction may

involve the production of prostaglandins, such as PGE2 (Li et al., 2005). With this in
mind, we examined changes in Ptgs2 expression following application of BzATP with
and without the addition of the P2X7 selective inhibitor, A438079. A438079 is a
recently developed antagonist that has been shown to specifically block P2X7 (Nelsen et
al., 2006; Donnelly-Roberts and Jarvis, 2007). We confirmed that BzATP activation of
P2X7 leads to significant increases in Ptgs2 expression at similar time points as
previously observed in our past studies (Grol et al., 2013; Na, 2016). Furthermore, we
showed that BzATP-induced expression of Ptgs2 is inhibited by A438079 and therefore
mediated through activation of P2X7.
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Dmp1 encodes dentin matrix acidic phosphoprotein 1, which is found in bone, dentin
and cementum (George et al., 1993).

Dmp1 is expressed by both osteoblasts and

osteocytes and is critical in bone mineralization. In this study, we saw significant Dmp1
expression at 3 hours as observed in our previous studies (Na, 2016). Again, A438079
completely inhibited Dmp1 expression, implicating P2X7 in this effect.

c-Fos is an immediate early gene, which encodes a transcription factor that plays a
critical role in regulating differentiation and proliferation of bone and cartilage cells
(Hipskind and Bilbe, 1998). Overexpression of c-Fos has been found to be associated
with the development of osteosarcomas and chondrosarcomas in mice, whereas failure
to express c-Fos leads to lack of osteoclasts and development of osteopetrosis in mice
(David et al., 2005; Wang et al., 1992). These findings suggest that c-Fos plays an
important role in the regulation of bone cells. In the present study, we confirmed Dr.
Na’s previous observation that BzATP leads to an increase of c-Fos expression at 30
minutes (Na, 2016).

Again, A438079 completely abolished c-Fos expression

implicating P2X7.
Thus, we have shown that in osteoblastic cells activation P2X7 stimulates expression of
Ptgs2, Dmp1 and c-Fos, which should lead to anabolic effects in bone. Our findings are
consistent with evidence from others implicating P2X7 in osteogenesis, including
reduced alkaline phosphatase activity in osteoblasts from P2X7 KO mice (Panupinthu et
al., 2008), decreased periosteal bone formation in P2X7 KO mice (Ke et al., 2003), and
their attenuated anabolic response to mechanical loading (Li et al., 2005). Furthermore,
an increased risk of osteoporosis in humans is associated with several polymorphisms in
P2X7 linked to impaired receptor function (Gartland et al., 2012; Jorgensen et al., 2012;
Ohlendorff et al., 2007). Our findings provide further evidence of a role for P2X7 in
stimulating bone formation.
3

Role of lipid signaling pathways in mediating effects of P2X7

Lysophosphatidic acid (LPA) is a lipid mediator that interacts with G protein-coupled
receptors and has been shown to be involved with osteoblast differentiation and

41
chemotaxis (Blackburn and Mansell, 2011; Sims et al., 2013; Sheng et al., 2015). There
are several receptors for LPA; LPA1 is the predominant receptor for LPA on osteoblastic
cells (Masiello et al., 2006). Several studies have shown that LPA1 plays a role in bone
formation. For example, Gennero et al. found that LPA1 KO mice displayed significant
bone defects and low bone mass, indicating that LPA1 may play an important role in
osteogenesis (Gennero et al., 2011). Another study found that inhibition of LPA1 in
human mesenchymal stem cells decreased LPA-induced rise in intracellular Ca2+ and
cAMP signaling as well as subsequent osteogenesis (Liu et al., 2010). LPA-treated
MC3T3-E1 cells show alterations in their cytoskeleton and elevations in Ca2+, effects
that resemble the osteoblastic cells’ response to fluid shear (Waters et al., 2007). Waters
et al. found that LPA-treated MC3T3-E1 cells expressed genes necessary for skeletal
repair, including several inflammatory mediators (Waters et al., 2007).
Prostaglandins (PGs) are important in inflammation and are instrumental in mediating
the effects of mechanical stress (Blackwell et al., 2010). In orthodontics, PGs have been
found to stimulate both osteoclastic bone resorption and osteoblastic bone formation
(Davidovitch et al., 1988; Yamasaki et al., 1984). PGE2 has four receptor subtypes that
it binds to: EP1-EP4 (Funk, 2001). MC3T3-E1 cells express both EP1 and EP4 receptor
subtypes (Suda et al, 1998).

The stimulatory effects of PGE2 on osteoblast

differentiation and subsequent bone formation are thought to be mediated by the EP4
receptor (Yoshida et al., 2002).
Previous results from our lab and others show that P2X7 activation is linked to the
production of lipid mediators, which may have osteogenic effects in bone. Li et al.
showed that response to mechanical loading and PGE2 release was impaired in P2X7
receptor deficient mice (Li et al., 2005). In our lab, Panupinthu et al. showed that
signaling through P2X7 induces production of LPA and PGE2, and enhances
osteogenesis (Panupinthu et al., 2007; Panupinthu et al., 2008). Panupinthu et al. found
that the LPA1/3 antagonist VPC-32183 abolished the effect of BzATP on mineral
deposition in rat calvarial cell cultures. Furthermore, Panupinthu et al. used ibuprofen to
block the effects of BzATP on PG synthesis. Similar to the actions of VPC-32183,
ibuprofen abolished the effects of BzATP on mineralization (Panupinthu et al., 2008).
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We examined the role of PGs and LPA in BzATP-induced Ptgs2 expression by
inhibiting PGE2 production and/or blocking the LPA receptor. In treating MC3T3-E1
cells with ibuprofen, an inhibition of Ptgs2 expression was seen. VPC-32183 also had an
inhibitory effect on BzATP-induced Ptgs2 expression. In combination, ibuprofen and
VPC-32183 completely abolished Ptgs2 expression.

Lastly, we examined the effects of PGE2 and LPA on Ptgs2 expression in MC3T3-E1
cells. We found that the addition of either lipid mediator individually did not have a
significant effect on Ptgs2 expression; however, the combined addition of PGE2 and
LPA significantly increased in Ptgs2 expression. We show for the first time that PGE2
and LPA have a synergistic effect that simulates BzATP-induced P2X7 activation. This
finding indicates that both lipid mediators are necessary and sufficient in combination to
mimic BzATP-induced P2X7 activation. Thus, they may play important roles in P2X7mediated osteogenesis and mechanotransduction.
4

Limitations of the study and suggestions for future studies

There are a few limitations of this study as outlined below.

a) Our study was limited to investigation of specific genes, but this was necessary
as a preliminary step to determine the types of genes being expressed in response
to various treatments administered. In addition, time constraints precluded us
from examining protein levels and in vitro mineralization.
b) In using a mouse osteoblast precursor cells line, we limit translation of our
results to human osteoblasts, as there are inherent species-specific differences
between mouse and human osteoblasts.
c) While our study was in vitro in nature, it provides a useful model for
understanding the effects of P2X7 receptor activation. These results may be
translatable to in vivo effects, but future studies will be needed to determine this.
A number of future studies would be useful to address these limitations and answer
questions that have arisen as a result of this study. These include:
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a) Other genes, including genes not regulated by dexamethasone (e.g. c-Fos), which
we would expect are regulated by pathways downstream of P2X7 other than PG
and LPA pathways.
b) Examine protein levels with a similar experimental design.
c) We expect that dexamethasone should inhibit P2X7-activated production of LPA
and PGE2. Future studies should directly measure the effects of dexamethasone
on the release of these lipid mediators.
d) Determine how PG and LPA interact synergistically. This would include
identifying: which LPA and PG receptors are involved, which signaling
pathways are activated downstream of the receptors, and how these pathways
interact to stimulate Ptgs2 expression.
e) A study done in a primary osteoblast cultures looking at an extended timeline
post BzATP treatment should clarify whether the expression of anabolic genes in
osteoblasts translates to increased matrix mineralization.
f) Others have shown that PG inhibitors block mechanically induced bone
formation in animal models (Cottrell and O-Connor, 2010). It would be
interesting to determine whether dexamethasone or LPA1/3 receptor antagonists
have similar effects. Similarly, it would be interesting to assess the effects of
these agents on orthodontic tooth movement in an animal model.
5

Relevance of the study in orthodontic tooth movement

Although the cellular mechanisms underlying orthodontic tooth movement (OTM) have
been clearly outlined, the precise pathways mediating mechanotransduction remain to be
elucidated.

In our study, we aimed to establish the role of P2X7 in anabolic gene

expression in osteoblastic cells.

In expanding our basic science knowledge and

understanding molecular mechanisms involved in OTM, we may design more
physiologic and efficient methods to achieve better orthodontic results. Any mechanism
involved with inhibiting or delaying the events contributing to mechanical stimulation
and subsequent bone remodeling may have negative consequences to OTM. Here we
show that the non-selective COX inhibitor ibuprofen has a negative effect on osteoblast
activation and potentially bone formation via its inhibition of Ptgs2 expression. This
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finding may assist in explaining why other studies have found that COX inhibitors, such
as indomethacin, have an inhibitory effect on OTM (Chumbley and Tuncay, 1986).
Since OTM is dependent upon the coordinated activity of osteoblasts and osteoclasts,
disruption in the activity of one of these cell types may inhibit efficient tooth movement.
Further implicating NSAIDs in altered bone remodeling, numerous studies have
indicated that NSAIDs may impair bone healing and repair (Cottrell and O-Connor,
2010). This is believed to occur due to inhibition of prostaglandin production, which
reduces osteoclast and osteoblast activation necessary for bone healing.

Although

evidence exists to suggest that low dose and short-term use of NSAIDs may not have a
significant effect on the rate of OTM clinically (Proffit, 2012; Fang et al., 2016), further
studies are needed to clarify future recommendations.
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Figure 16: Summary of the findings.
In conclusion, we show that P2X7 is the receptor activated by BzATP to induce anabolic
gene expression in osteoblasts. Genes such as Ptgs2, Dmp1 and c-Fos are up regulated
through BzATP stimulation and are abolished through inhibition with a P2X7-specific
antagonist, A438079. Furthermore, we show that a P2X7-LPA-PGE2 axis may have a
regulatory role in osteogenesis.
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APPENDICES
Appendix A: Results presented without the normalization as percentage of
maximum gene expression.

Data are shown as relative gene expression of respective genes
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Appendix B: Permission to use Figure 2.
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